griseofulvin (Discontinued)

Brand and Other Names:Grifulvin V, Gris-PEG
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

oral suspension, microsize

  • 125mg/5mL

tablet, microsize

  • 500mg (Grifulvin V)

tablet, ultramicrosize

  • 125mg (Gris-PEG)
  • 250mg (Gris-PEG)

Tinea Infection

Infections affecting skin, body, hair/beard, or nails

Microsize

  • Tinea corporis, cruris, or capitis: 500 mg/day PO
  • Tinea pedis or unguium: 1000 mg/day PO as single daily dose or divided q12hr

Ultramicrosize

  • Tinea corporis, cruris, or capitis: 375 mg/day PO
  • Tinea pedis or unguium: 250 mg PO q8hr

Treatment duration

  • Dependent on infection site
  • Tinea corporis: 2-4 weeks
  • Tinea capitis: 4-6 weeks; may be up to 8-12 weeks
  • Tinea pedis: 4-8 weeks
  • Tinea unguium: 4-6 months

Dosing considerations

  • Absorption increased with fatty meals

Dosage Forms & Strengths

oral suspension, microsize

  • 125mg/5mL

tablet, microsize

  • 500mg (Grifulvin V)

tablet, ultramicrosize

  • 125mg (Gris-PEG)
  • 250mg (Bris-PEG)

Tinea Infection

Infections affecting skin, body, hair/beard, or nails

<2 years old: Safety and efficacy not established

Microsize

  • 11 mg/kg/day PO as single dose or divided q12hr  
  • 13.6-22.7 kg (30-50 lb): 125-250 mg/day
  • >22.7 kg (>50 lb): 250-500 mg/day
  • Off-label: 10-20 mg/kg/day PO divided q12hr

Ultramicrosize

  • 7.3 mg/kg/day PO
  • 13.6-22.7 kg (30-50 lb): 82.5-165 mg/day
  • >22.7 kg (>50 lb): 165-330 mg/day
  • Off-label: 5-15 mg/kg/day PO divided q12hr; not to exceed 750 mg/day

Treatment duration

  • Dependent on infection site
  • Tinea corporis: 2-4 weeks
  • Tinea capitis: 4-6 weeks; may be up to 8-12 weeks
  • Tinea pedis: 4-8 weeks
  • Tinea unguium: 4-6 months

Dosing considerations

  • Absorption increased with fatty meals
Next:

Interactions

Interaction Checker

and griseofulvin

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 
            Previous
            Next:

            Adverse Effects

            Frequency Not Defined

            Rash (most common)

            Urticaria (most common)

            Headache

            Fatigue

            Dizziness

            Insomnia

            Mental confusion

            Photosensitivity

            Nausea

            Vomiting

            Epigastric distress

            Diarrhea

            GI bleeding

            Leukopenia

            Hepatotoxicity

            Proteinuria

            Nephrosis

            Oral thrush

            Angioneurotic edema (rare)

            Drug-induced lupuslike syndrome (rare)

            Menstrual irregularities (rare)

            Paresthesia (rare)

            Postmarketing Reports

            Severe skin reactions (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis) and erythema multiforme

            Liver toxicity

            Previous
            Next:

            Warnings

            Contraindications

            Hypersensitivity

            Porphyria

            Hepatocellular failure

            Pregnancy

            Cautions

            Severe skin reactions (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis) and erythema multiforme reported, some resulting in hospitalization or death; discontinue if severe skin reaction occurs

            Elevations in AST, ALT, bilirubin, and jaundice reported, some resulting in hospitalization or death; discontinue if jaundice occurs

            Patients on prolonged therapy with any potent medication should be under close observation; periodic monitoring of organ system function, including renal, hepatic and hematopoietic, should be done

            Previous
            Next:

            Pregnancy & Lactation

            Pregnancy category: X; no adequate and well-controlled studies in pregnant women, but animal studies have shown embryotoxic and teratogenic effects

            Lactation: Excretion in milk unknown; avoid use because of potential tumorigenicity

            Pregnancy Categories

            A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA: Information not available.

            Previous
            Next:

            Pharmacology

            Mechanism of Action

            Fungistatic; deposited in keratin precursor cells and is tightly bound to new keratin, and this increases resistance to fungal invasion

            Absorption

            Absorption of ultramicrosize griseofulvin absorption is almost complete; absorption of microsize griseofulvin is variable (25-70% of oral dose); enhanced by ingestion of fatty meal (GI absorption of ultramicrosize is 1.5 times that of microsize)

            Distribution

            Drug crosses placenta

            Metabolism

            Extensively metabolized by liver; hepatic CYP3A4 induced

            Elimination

            Half-life: 9-22 hr

            Excretion: Urine (<1% as unchanged drug), feces, perspiration

            Previous
            Next:

            Images

            Previous
            Next:
            Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.